AxoGen AI Stock Analysis
Want to see AXGN full AI Analyst Report?
AxoGen (AXGN) AI Stock Analysis
AxoGen
(NASDAQ:AXGN)
AXGN scores well on improving fundamentals and cash flow, plus a clearly bullish price trend and a strong, guidance-raising earnings update. The overall score is held back primarily by weak valuation signals tied to ongoing profitability limitations (negative P/E) and some near-term margin/cost and integration risks highlighted on the call.
AxoGen (AXGN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.31B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.55M
- Price to Earnings (P/E)
- -85.5
- Beta (1Y)
- 1.19
- Revenue Growth
- 24.32%
- EPS Growth
- -1274.47%
- Country
- US
- Employees
- 622
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
AxoGen Business Overview & Revenue Model
Company Description
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance...
How the Company Makes Money
AxoGen primarily makes money by selling peripheral nerve repair products to hospitals, ambulatory surgery centers, and other healthcare providers for use in surgical procedures. Revenue is generated from product sales across its portfolio, which incl...
AxoGen Earnings Call Summary
The call was strongly positive, supported by 26.2% year-over-year revenue growth, accelerating breast performance, improved adjusted profitability, expanded payer coverage, clinical-study progress, completion of the BioCircuit acquisition, and raised full-year revenue guidance. The principal challenges were lower year-over-year gross margin, expected fourth-quarter margin pressure, higher operating and acquisition-related costs, Aetna's utilization-management restriction, and future amortization and integration considerations. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full-year 2026, Axogen now expects revenue growth of at least 29% or revenue of at least $290 million, including at least $7 million of revenue from BioCircuit; excluding BioCircuit, organic revenue is expected to be at least $283 million, representing organic growth of at least 26%, with gross margin of at least 73% and positive free cash flow. The guidance does not assume material benefit from payer coverage decisions beyond what's already known or from prostate market development, and BioCircuit revenue guidance contemplates some level of integration or disruption risk; the purchase-accounting inventory step-up could negatively impact gross margin in the fourth quarter and for the full year relative to current expectations. Gross margin is expected to decline in the fourth quarter sequentially and to be slightly less than the second quarter. Full-year 2027 is expected to be more in line with full-year 2026, with formal 2027 guidance in the first quarter; the $34 million of NerveTape sales next year is incremental and net of cannibalization. Prostate is not included in current or long-range guidance, and extremities are expected to range from very high single digit to low double-digit growth quarter-to-quarter, year in, year out.
AxoGen Financial Statement Overview
Summary
Revenue is accelerating (to $266.9M TTM) with strong gross margins (~74–82%) and a notable improvement in cash generation (TTM operating cash flow $28.4M; free cash flow $22.0M). The main drag is still profitability: net income remains negative in TTM with negative ROE, indicating the business has not yet converted growth into durable earnings.
Income Statement
56NeutralBalance Sheet
72PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 266.93M | 225.21M | 187.34M | 159.01M | 138.58M | 127.36M |
| Gross Profit | 198.00M | 167.35M | 141.98M | 121.87M | 108.81M | 104.43M |
| EBITDA | -21.24M | 192.00K | 6.08M | -13.33M | -23.47M | -20.89M |
| Net Income | -31.92M | -15.70M | -9.96M | -21.72M | -28.95M | -26.98M |
Balance Sheet | ||||||
| Total Assets | 550.34M | 221.69M | 203.73M | 196.83M | 195.39M | 208.02M |
| Cash, Cash Equivalents and Short-Term Investments | 348.07M | 35.55M | 33.48M | 31.02M | 48.79M | 84.09M |
| Total Debt | 19.47M | 67.63M | 68.69M | 69.29M | 67.43M | 67.45M |
| Total Liabilities | 54.24M | 92.84M | 99.82M | 101.16M | 94.39M | 95.47M |
| Stockholders Equity | 496.10M | 128.85M | 103.91M | 95.67M | 101.00M | 112.55M |
Cash Flow | ||||||
| Free Cash Flow | 16.31M | -2.93M | 11.00K | -20.63M | -37.32M | -41.80M |
| Operating Cash Flow | 22.63M | 812.00K | 4.54M | -5.72M | -16.07M | -13.40M |
| Investing Cash Flow | -22.36M | -5.32M | -10.30M | 19.25M | -3.20M | -23.65M |
| Financing Cash Flow | 293.55M | 10.50M | 2.29M | 1.95M | 1.79M | 20.45M |
AxoGen Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AXGN, the sentiment is Positive. The current price of 55.38 is above the 20-day moving average (MA) of 47.37, above the 50-day MA of 43.41, and above the 200-day MA of 40.63, indicating a bullish trend. The MACD of 4.04 indicates Negative momentum. The RSI at 68.27 is Neutral, neither overbought nor oversold. The STOCH value of 65.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AXGN.
AxoGen Risk Analysis
AxoGen disclosed 60 risk factors in its most recent earnings report. AxoGen reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksAxoGen Peers Comparison
Overall Rating
AXGN68Neutral
BVS66Neutral
OFIX44Neutral
TELA43Neutral
IART40Underperform
XTNT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | $3.31B | -85.46 | -11.34% | ― | 24.32% | -1274.47% | |
| 66Neutral | $881.37M | 12.35 | 27.23% | ― | 3.87% | 623.68% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $277.17M | -6.14 | -10.32% | ― | 2.12% | 63.59% | |
| 43Neutral | $34.42M | -1.05 | 425.91% | ― | 1.46% | 15.79% | |
| 40Underperform | $1.09B | 84.36 | 1.24% | ― | 0.84% | ― | |
| 39Underperform | $29.43M | -2.23 | -36.21% | ― | -24.44% | -1012.80% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AXGN | AxoGen | 55.38 | 31.37 | 130.65% | |
| IART | Integra Lifesciences | 13.98 | 2.56 | 22.42% | |
| OFIX | Orthofix Medical Inc. | 6.80 | -7.60 | -52.78% | |
| XTNT | Xtant Medical Holdings Inc | 0.21 | -0.44 | -67.60% | |
| TELA | Tela Bio, Inc. | 0.76 | -0.42 | -35.51% | |
| BVS | Bioventus, Inc. | 10.46 | 3.47 | 49.64% |
AxoGen Corporate Events
AxoGen Highlights Prostate Nerve Reconstruction Opportunity and Clinical Results
PositiveOn November 9, 2026, Axogen posted a corporate presentation outlining its prostate nerve reconstruction opportunity. The presentation described an estimated $754 million total addressable market tied to about 110,000 annual robotic-assisted prostatec...
AxoGen Raises Outlook on Strong Q3 2026 Results
PositiveAxoGen Inc., a U.S.-based leader in peripheral nerve repair technologies, markets a portfolio of nerve grafts, connectors, protectors, soft tissue matrices, and NerveTape aimed at restoring motor and sensory function following traumatic or surgical n...
AxoGen Acquires BioCircuit, Expands Peripheral Nerve Portfolio
PositiveOn October 1, 2026, AxoGen completed its acquisition of privately held BioCircuit Technologies, adding NerveTape, the first FDA-cleared sutureless device for repairing transected peripheral nerves, to its product lineup. Management framed the transac...
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio
PositiveOn September 9–10, 2026, Axogen agreed to acquire BioCircuit Technologies for $200 million in cash, with BioCircuit to become a wholly owned subsidiary after a spin‑out of its unrelated electronics business. The deal, expected to close in the fourth...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026
